HemeBiotech A/S gets Swedish CTA for its first product  

HemeBiotech A/S to initiate clinical trials of a recombinant enzyme for Acute Intermittent Porphyria

HemeBiotech A/S has received Swedish Medicines Agency approval to initiate phase I/II clinical trials for the company’s first product, a recombinant enzyme for Acute Intermittent Porphyria (AIP). Over 3 years, the company has moved the product from idea to full scale manufacturing. AIP is an inherited disease with serious clinical symptoms including severe pain, increased blood pressure and neurological disturbances. The news is reported on the company's website.


HemeBiotech received initial venture capital funding of DKK 60 million (USD 7.8 million) from BankInvest A/S and Pen-Sam and DKK 46 million (USD 6 million) from Danish Government loans. The company has recently received an additional DKK 54 million (USD 7 million) from existing investors and IPCONS ApS. HemeBiotech was founded in 1998 and has headquarters in Medicon Valley north of Copenhagen, laboratories and production facilities in Symbion Research Park Copenhagen, and research laboratories in Stockholm, Sweden. The company also has a network of research and contract partners in the US and Europe.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×